This ASX dividend share was one of my biggest buy regrets

Hopefully you don't make the same investing mistakes I did with this one.

| More on:
Disappointed elderly man with regret sits at his desk with his hand to his forehead looking at his laptop and learning about the Lynas share price fall

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

As someone who has been investing in ASX shares for many years now, I have fortunately had a few successes. But I have also, unfortunately, had a few stinkers as well.

I don't wish I could take these back in hindsight because every mistake is a lesson that stops us from making bigger mistakes (with more money) down the road. But that doesn't mean that I don't still regret some of my mistakes. I'm only human, after all.

So today, I'm going to discuss one of my biggest regrets when it comes to an ASX share buy. Hopefully, you can learn the same painful lessons that I did, without the money-losing part.

The mistake in question was buying shares of WAM Global Ltd (ASX: WGB). WAM Global is a listed investment company (LIC) run by Wilson Asset Management (the WAM).

It only launched in 2018, and I was one of the buyers who participated in the initial public offering (IPO). Why? Well, I had an idea that WAM was a successful asset manager, thanks to the high dividend yields offered by some of their other LICs like WAM Capital Ltd (ASX: WAM). Not to mention a slick marketing campaign.

So WAM Global IPOed for $2.20 a share in June 2018, and I was now a new owner of this company.

Breaking down one of my biggest ASX share buy regrets

Unlike most WAM LICs, WAM Global invests in companies from outside the ASX, as its name implies. I was excited by the ambitious scope of this project.

But after a while, my faith was fading. It wasn't just that the WAM Global share price fell at IPO and continued to fall. Perhaps WAM was overambitious when it came to its asking price. Either way, it didn't take me long to start racking up my first paper losses. By the end of 2018, WAM Global shares were under $2 each.

But that wasn't why I was starting to question my decision. I am patient when it comes to waiting for an investment thesis to pay off. What I had little patience for was a lack of transparency.

WAM Global rarely discussed its actual shareholder returns. What it did discuss was its portfolio's underlying performance, which is not the same thing when it comes to an LIC. But even that did not account for the liberal management fees I, alongside other shareholders, were paying.

I had to go digging to find out that WAM Global charges its shareholders an annual management fee of 1.25% per annum. Which is not reflected in its portfolio performance metrics.

Late last year, I sold out of my WAM Global shares. I wish I had done so sooner in hindsight, but I still crystallised a loss on my original investment. I think I may have broken even after accounting for the dividend returns. But even so, this is after more than four years of holding those shares. Thus, we get to the conclusion of one of my biggest ASX share buy regrets.

I would have done so much better just owning an index fund. That way, I could have gotten some decent returns and paid a far more appealing management fee of under 0.1% per annum in doing so. Heck, I probably would have been better off keeping the cash in a term deposit.

But you live and you learn. Yesterday, WAM Global closed at $1.87 a share. I'm certainly glad I didn't wait any longer than I did to wipe my hands off one of my biggest investing regrets.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Opinions

A mature-aged couple high-five each other as they celebrate a financial win and early retirement
Dividend Investing

How to retire early with these ASX titans

There are so many mouth-watering dividend stocks in Australia, those who want to quit work have options.

Read more »

A woman looks unsure as she ladles mixture into a pan surrounded by small appliances
Opinions

My 2024 warning: Don't get (completely) lost in the passive income sauce

It's easy to become fixated on BIG yields to ease the cost of living pressures next year. Here's my word…

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Here's why I can't wait to buy Chemist Warehouse shares

Chemist Warehouse would ticks all of my boxes for a great investment.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Opinions

Sitting on cash? These 3 ASX shares could be great buys

Against shares, cash is still trash in my view...

Read more »

man in old fashioned suit and hat looking through magnifying glass
Opinions

2 undervalued ASX shares I think are set for a bull run

I think both of these ASX shares are primed to do well.

Read more »

Five arrows hit the bullseye of five round targets lined up in a row, with a blue sky in the background.
Healthcare Shares

When might CSL shares hit the $300-mark again?

CSL is on track for $300, if one broker is to be believed.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

2 ASX healthcare shares I think are overdue for a big rally

I think these early stage drug companies could have a barnstorming 2024.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Opinions

The top ASX shares I'd buy with $3,000 right now

It’s a great time to invest in long-term growth shares.

Read more »